

1	Letter from the President Rick Doblin
3	Bastaans Method of Drug-Assisted Therapy A Preliminary Follow-Up Study with Former Clients Hans C. Ossebaard and Nicole Maasté Dutch therapist Jan Bastaans worked with LSD, psilocybin and ketamine with many of his clients before his retirement in 1988.
10	Marijuana Research Update Rick Doblin A recent federal policy shift now requires NIDA to sell marijuana to non-government-funded studies.
11	Successful Outcome of a Single LSD Treatment in a Chronically Dysfunctional Man Gary Fisher, Ph.D. The author shares a story of a young man's single session with LSD.
15	New Online Project: Psychedellic Research Around the World Sylvia Thyssen A new project on the MAPS website tracks the status of current research. Studies that are being planned, studies in progress, and completed studies are listed here.
21	Project Updates: Salvia Divinorum and the Second Generation Project Updates on studies announced in the last issue of the <i>Bulletin</i> , one with <i>Salvia divinorum</i> and meditation, the other with children of parents who value psychedelics.
22	Ayahasca and Cancer: A Postscript Donald Topping, Ph.D. This is a follow-up to an article printed in last year's "ayahasca issue" of the <i>MAPS Bulletin</i> . Topping elaborates on his personal interpretation of how ayahasca works.
26	Readers' Forum How to join MAPS' online moderated mailing list. Dutch bulletin goes out of print.
27	Letter from the MAPS Florida Office Sylvia Thyssen and Carla Higdon
28	Conference announcements Amazonian Shamanism and Spirituality, Worlds of Consciousness, and AllChemical Arts: Psychoactive Creativity
30	MAPS Membership and Renewal Information

MAPS (Multidisciplinary Association for Psychedelic Studies) is a membership-based organization working to assist psychedelic researchers around the world design, obtain governmental approval, fund, conduct and report on psychedelic research in humans. Founded in 1986, MAPS is an IRS approved 501 (c)(3) non-profit corporation funded by tax deductible donations. MAPS has previously funded basic scientific research into the safety of MDMA (3,4, methylendioxyamphetamine, Ecstasy) and has opened a Drug Master File for MDMA at the U.S. Food and Drug Administration. MAPS is now focused primarily on assisting scientists to conduct human studies to generate essential information about the risks and psychotherapeutic benefits of MDMA, other psychedelics, and marijuana, with the goal of eventually gaining government approval for their medical uses. Interested parties wishing to copy any portion of this publication are encouraged to do so and are kindly requested to credit MAPS including name and address. The *MAPS Bulletin* is produced by a small group of dedicated staff and volunteers. Your participation, financial or otherwise, is welcome.

© 1999 MAPS
Multidisciplinary Association for Psychedelic Studies, Inc. (MAPS)
2105 Robinson Avenue,
Sarasota, FL 34232 USA
Phone: 941/924.6277
Fax: 941/924.6265
Email: info@maps.org
URL: <http://www.maps.org>